

Identification of Hub Genes in Diabetic Nephropathy by an Integrated Bioinformatic Analysis

Chenchun Chen

Guangxi Medical University <https://orcid.org/0000-0002-2598-5585>

Xiaoqiang Qiu (✉ xqqiu9999@163.com)

Guangxi Medical University

Research Article

Keywords: diabetic nephropathy (DN), differentially expressed genes (DEGs), weighted gene co-expression network analysis (WGCNA), hub gene

Posted Date: July 20th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-703904/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

23 COL1A2, MS4A6A, CD163, CLEC10A, MOXD1, IQGAP2, GHR) identified as
24 significant DN-associated genes. Furthermore, the expression level of these hub genes
25 was confirmed in the GSE96804 dataset.

26 **Conclusions:** These findings provide new insight into DN pathogenesis, which may
27 enhance our fundamental knowledge of the molecular mechanisms underlying this
28 disease.

29 **Key words:** diabetic nephropathy (DN), differentially expressed genes (DEGs),
30 weighted gene co-expression network analysis (WGCNA), hub gene

31 **Background**

32 The prevalence of diabetes and its complications poses a major threat to global health,
33 has contributed tremendously to the burden of mortality and disability (1). Acute
34 metabolic complications of diabetes associated with mortality include hyperglycemia
35 and coma due to hypoglycemia(2). While the most devastating consequence of diabetes
36 is its long-term vascular complications(3, 4). These complications are wide-ranging and
37 result, at least in part, from vascular damage caused by chronically elevated blood
38 glucose levels(5). Diabetic microvascular complications (nephropathy, retinopathy, and
39 neuropathy), which are long-term complications that affect small blood vessels, usually
40 affect those with a chronic or uncontrollable disease, but they can also be observed in
41 those who have been diagnosed or have not yet made a diagnosis of diabetes(6).

42 Diabetic nephropathy (DN) is one of the most fatal long-term complications of diabetes
43 and a leading cause of chronic kidney disease (7). The main signatures of DN usually
44 include glomerular scarring, proteinuria, a progressive decline in renal function, and

45 even end-stage renal disease (ESRD), which are attributed to tubular interstitial fibrosis,
46 hypertrophy, and dilatation of the glomerular mesentery, thickening of the glomerular
47 basement membrane, loss of foot cell peduncles, and inflammation due to monocyte
48 and macrophage infiltration (7, 8). The pathophysiology of DN is complex, involving
49 interactions between genetic factors, epigenetic factors, and the environment.
50 Diabetogenic stimuli, such as high blood glucose levels; advanced glycation end
51 products (AGEs); growth factors including transforming growth factor β 1 (TGF- β 1)
52 and platelet-derived growth factor and inflammatory cytokines, which have been
53 implicated in the pathogenesis of DN due to their detrimental effects on multiple renal
54 cell types(9-11). Although the pathophysiology of DN is continually being elucidated,
55 the underlying molecular mechanisms of DN progression are not fully understood.
56 Advances in histological techniques and the integration of high-dimensional data
57 through systems medicine approaches can provide the molecular mechanism of action
58 for drugs and disease progression pathways (12). Genomic data related to various
59 diseases are stored in public repositories, which can be easily accessed to obtain
60 meaningful information and make novel discoveries (13). Transcriptomic analysis
61 during the development of DN may be of great potential value for timely diagnosis and
62 timely treatment to prevent progression to end-stage renal disease.

63 In the present study, transcriptomic data of human DN from Gene Expression Omnibus
64 (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) were analyzed with RRA to identify
65 differentially expressed genes (DEGs) between DN tissues and normal subjects (14).
66 These DEGs were adopted into the Gene Ontology (GO) and Kyoto Encyclopedia of

67 Genes and Genomes (KEGG) analyses. The protein-protein interaction (PPI) network
68 was further constructed to understand cellular mechanisms and interactions between
69 cell's molecular constituents of selected genes. In addition, the top 25% of genes with
70 the greatest variance in the dataset were extracted to perform weighted gene co-
71 expression network analysis (WGCNA). Ten genes were selected as key genes based
72 on the screening conditions of module membership (MM) >0.8 and gene significance
73 (GS)>0.7. Finally, the expression level of these key genes was validated in another
74 expression profiling of DN in GSE96804.

75 **Methods**

76 **Datasets selection and data preprocessing**

77 The study design was conducted in the form of a flow diagram (Figure 1). Two
78 appropriate gene expression profiles were downloaded from the Gene Expression
79 Omnibus (GEO) database. The selection datasets were as follows: the GSE30528
80 (Affymetrix Human Genome U133A 2.0 Array) dataset, with a total of 9 DN samples
81 and 11 normal samples, and the GSE96804 (Affymetrix Human Transcriptome Array
82 2.0 [transcript (gene) version) dataset, with a total of 41 DN samples and 20 normal
83 samples. In addition, the clinical characteristics of sample information are available
84 online.

85 **Identification of reliable DEGs**

86 The series matrix file of glomeruli samples with normal and DN in the dataset
87 GSE30528 was obtained from the GEO. The R package "limma" was utilized for data
88 analysis, linear models, and screen the DEGs between DN samples and normal samples

89 (15). Genes with adjusted p-value < 0.05 and $|\log_2 \text{fold change (FC)}| > 1$ were considered
90 as significant DEGs. “Pheatmap” (R package) was performed to visualize the
91 expression patterns of the top 200 DEGs (top 100 up-regulated genes and top 100 down-
92 regulated genes according to adjusted P).

93 **Function enrichment and pathway analysis**

94 To study the functional annotation and signaling pathways of the DEGs, Gene Ontology
95 (GO) term enrichment analysis and Kyoto Encyclopedia of Genes and Genomes
96 (KEGG) pathway analysis were practiced with the R package “clusterprofiler”(16). The
97 GO categories of biological process (BP), molecular function (MF), and cellular
98 component (CC) were shown separately. The GO term enrichment and KEGG pathway
99 analysis with adjusted p-value < 0.05 were considered statistically significant.

100 **PPI network of DEGs**

101 To explore the group of proteins encoded by the list of genes, the Search Tool for the
102 Retrieval of Interacting Genes/Proteins (STRING) database ([http://www. string-db.org/](http://www.string-db.org/))
103 was utilized to assess PPI information. Meanwhile, the cytohubba plug-in of Cytoscape
104 software (NRNB, National Resource for Network Biology, US) was applied to PPI
105 network visualization and hub genes selection (17).

106 **Co-expression network analysis of DEGs**

107 The R package Weighted correlation network analysis “(WGCNA)” is a comprehensive
108 collection of R functions for performing various aspects of weighted correlation
109 network analysis. In this study, the top 25% of genes with the greatest variance in the
110 dataset GSE30528 were extracted as the input data for subsequent WGCNA. The

111 adjacency matrix was converted into a topological overlap matrix (TOM). Genes were
112 divided into different gene modules based on TOM-based difference dissimilarity
113 measures. Here, the power of $\beta = 19$ (scale-free $R^2 = 0.89$) was set as the soft threshold
114 to ensure a scale-free network. The modules with the highest correlation with clinical
115 features were selected to explore their function. Genes in the module with gene
116 significance (GS) > 0.3 and module membership (MM) > 0.8 were defined as key genes.

117 **Statistical analysis**

118 The results were presented as mean \pm standard error mean (S.E.M.). Statistical analysis
119 was performed with IBM SPSS Statistics 25.0 software (SPSS, Inc., Chicago, IL, USA).
120 Significant differences were measured by one-way ANOVA for two groups of data
121 followed by a Tukey's posthoc comparison. P value < 0.05 was considered statistically
122 significant.

123 **Results**

124 **Identification of DEGs**

125 The workflow for identification, validation, function enrichment, and pathway analysis
126 of DEGs was shown in Figure 1A. The DEGs screening criteria were set in the limma
127 package, and a total of 113 up-regulated and 311 down-regulated significant DEGs were
128 identified from the genes of glomeruli samples with DN patients and normal subjects.
129 The volcano plot displayed the distribution of DEGs between DN and normal glomeruli
130 samples (Figure 1B). Compared to normal subjects, the gene C1QA was the most
131 significant up-regulated gene (P value = $2.66E-08$, adjusted P value = $7.11E-06$),
132 followed by SERPINE2 (P value = $3.10E-07$, adjusted P value = $3.53E-05$) in DN samples.

133 C1QA-associated activation of the complement system was found in patients with
134 diabetic nephropathy (18). Immunostaining for C1QA was also found in the renal cortex
135 and medulla oblongata of sheep with acute kidney injury (19). Meanwhile the genes
136 ZNF415 (P value=7.44E-11, adjusted P value=8.09E-07), LOX (P value=1.81E-10,
137 adjusted P value=8.09E-07) and CA10 (P value=2.31E-10, adjusted P value=8.09E-07)
138 were the most significant down-regulated genes in DN samples. The top 100 up-
139 regulated and down-regulated DEGs were shown in the heatmap (Figure 1C).

140 **Function enrichment of DEGs**

141 To further understand the function of the identified DEGs for diabetic nephropathy, the
142 DEGs were subjected to perform GO analyses in biological process, molecular function,
143 and cellular component. The bar plot was implemented to visualize the analysis of
144 enriched GO terms. In the terms of biological processes, kidney development, renal
145 system development, urogenital system development, and positive regulation of cell
146 adhesion were considered as the significant enrichment (Figure 2A). The actin-binding
147 and cell adhesion molecule binding was the most significantly enriched GO term in
148 molecular function (Figure 2B). What's more, for cellular components, extracellular
149 matrix and adherens junction were the most significantly enriched GO terms (Figure
150 2C).

151 **Pathway analysis of DEGs**

152 To explore the molecular interaction, reaction, and relation networks in diabetic
153 nephropathy. The DEGs were enriched in the KEGG pathway database. The KEGG
154 pathway enrichment analysis indicated that the DEGs were notably accumulated in the

155 PI3K-Akt signaling pathway and the Focal adhesion pathway (Figure 3A). Based on
156 accumulated evidence, the PI3K-Akt signaling pathway is necessary for normal
157 metabolism and its imbalance leads to obesity and the development of type 2
158 diabetes(20).

159 **Construction of PPI network**

160 To gain insight into cellular physiology in normal and diabetic nephropathy states, the
161 PPI networks of DEGs were constructed and presented in Figure 4A. The minimum
162 required interaction score was set at the highest confidence (confidence=0.9) and
163 disconnected nodes in the network were hidden. The Cytoscape plugin cytoHubba
164 provided 11 topological analysis methods to rank nodes in a network by the network
165 features (17). To explore important nodes/hubs and fragile motifs in an interactome
166 network, the top 30 essential genes ranked by Maximal Clique Centrality (MCC) scores
167 were selected. Four hub modules and top 30 essential genes were presented in the PPI
168 network (Figure 4B). The top 10 genes ranked by MCC were C3, GPR183, GPR18,
169 P2RY14, CCL5, CXCL6, CCL19, SST, ADRA2A, and FN1.

170 **Construction of gene co-expression modules**

171 To find the key modules that were most relevant to the clinical features of diabetic
172 nephropathy, the top 25% of genes with the greatest variance in the dataset GSE30528
173 were extracted to perform WGCNA. Clinical characteristics were retrieved from
174 sample information online. The soft thresholding power β was first calculated, to which
175 the co-expression similarity is raised to calculate adjacency. Here, we set the soft
176 thresholding power β as 19 in the ensuing analysis. The scale independence reached

177 0.89 (Figure 5A) and with a relatively high-average connectivity (Figure 5B). Then, we
178 constructed the gene network and identified modules using a one-step network
179 construction function. Finally, we eventually identified 11 gene co-expression modules
180 (Figure 6A).

181 **Analysis of gene co-expression modules**

182 The relationship between identified modules was mapped (Figure 7A). Subsequently,
183 we transformed the weighted adjacency matrix into a topological overlap matrix (TOM)
184 and computed the corresponding heterogeneity to minimize noise and spurious
185 association. The heat map depicted the TOM between selected genes included in the
186 analysis. Lighter colors indicated low overlap, while progressively darker reds
187 indicated increasing overlap. Higher TOM values suggest that a pair of genes are more
188 likely to connect and to a set of shared genes. The analysis showed that gene expression
189 was relatively independent between modules.

190 **Identification of key modules**

191 The modules and clinical characteristics were correlated for searching the most
192 significant associations. Our results indicated that the module magenta was most
193 significantly negatively correlated with diabetic nephropathy (correlation
194 coefficient=0.92, P-value =8E-10), while module green was most significantly
195 positively correlated with diabetic nephropathy (correlation coefficient=0.72, P-value
196 =2E-04) (Figure 8A). Based on the correlation coefficient results we identified the
197 green module as the key module for further analysis.

198 **Identification and validation of key genes**

199 There were 120 genes were included in module green. By setting module membership
200 (MM) >0.8 and gene significance (GS) >0.7, 10 genes were selected for key genes:
201 RNASE6, CD1C, SASH3, COL1A2, MS4A6A, CD163, CLEC10A, MOXD1,
202 IQGAP2, GHR (Table 1). Then, gene expression profiles from the GSE96804 dataset
203 were used to validate the expression of these key genes in diabetic nephropathy. As
204 shown in Figure 9A-J, the expression of the up-regulated key genes RNASE6, CD1C,
205 SASH3, COL1A2, MS4A6A, CD163, CLEC10A, AND MOXD1 in diabetic
206 nephropathy were significantly elevated compared with normal subjects. While the
207 expression of IQGAP2 and GHR in diabetic nephropathy was remarkably down-
208 regulated. Furthermore, the regulation of these key genes was all consistent with the
209 relevance between gene expression and clinical characteristics. These results show that
210 the selected key genes are generally differentially expressed in diabetic nephropathy.

211 **Discussion**

212 Diabetic nephropathy is a highly prevalent complication of diabetes mellitus (DM),
213 which is influenced by both environmental and genetic factors (8). Clinically, patients
214 with DN generally have a poorer prognosis compared with patients without DN. Recent
215 studies on DN have had limited success, in part because not all patients diagnosed with
216 DN have renal dysfunction as a result of their diabetes mellitus. In the development and
217 progression of diabetic nephropathy, genetic factors and signal transduction pathways
218 influence the expression of genes and phenotypes associated with DN. Therefore, the
219 escalating rates of DN indicate the need for a more in-depth understanding of the
220 underlying molecular mechanisms to explore susceptibility modules and genes to

221 identify better therapies for this disease (8, 21).

222 In the present study, 424 genes were differentially expressed in glomeruli samples with
223 DN patients and normal subjects. Among these 424 DEGs, 113 genes were upregulated
224 and 311 genes were downregulated. The complement system was identified as one of
225 the significantly regulated pathways in diabetic kidneys according to the analysis of
226 glomerular and tubular (22). Similar to the previous results, the expression of C1QA
227 was markedly upregulated in DN samples. In addition, analysis of the types of immune
228 cells in the glomerulus of diabetic mice reveals that the cells in the immune clusters are
229 predominantly macrophages, showing high expression of typical macrophage markers
230 such as C1QA, Cd74, and Adgre1 (23).

231 GO term enrichment analysis and KEGG pathway analysis for functional annotation
232 were performed with both upregulated and downregulated genes. GO term analysis
233 revealed that the DEGs were mainly associated with cell adhesion molecule binding,
234 glycosaminoglycan binding, actin binding, and enzyme inhibitor activity. To date, four
235 families of cell adhesion molecules have been identified: globulins, selectins, integrins,
236 and immune Globulin CAM superfamily (24). Leukocytes bound to the activated
237 endothelium via cell adhesion molecule and its receptors and then migrated into the
238 tissue, where they then began the inflammatory process (25). With the further induction
239 of these pathways, massive microvasculature is injured and eventually leads to the
240 complications observed in T2DM patients (26). The KEGG pathway enrichment
241 analysis indicated that the DEGs were accumulated in the phosphatidylinositol-3-
242 kinase/protein kinase B (PI3K-Akt) signaling pathway, Focal adhesion, Regulation of

243 actin cytoskeleton, Rap1 signaling pathway, and MAPK signaling pathway. Recent
244 experimental evidence suggests that PI3K-Akt is involved in ROS effects on the
245 activation of Nrf2 by oxidative stress (27). Diabetic nephropathy may be improved by
246 antioxidant action and thus decreased ROS production (28). These studies further
247 confirm that the PI3K-Akt signaling pathway plays a critical role in the progression of
248 DN (29, 30).

249 Moreover, the PPI networks were constructed, and 30 outstanding genes were identified
250 by Maximal Clique Centrality scores. The top 10 genes (C3, GPR183, GPR18, P2RY14,
251 CCL5, CXCL6, CCL19, SST, ADRA2A, and FN1) were considered weighty. Some of
252 these genes have been generally demonstrated in previous studies for their
253 overexpression and relevance in DN. In several animal models of diabetes, Ig and C3
254 deposition, which was associated with macrophage infiltration, is thought to be in
255 glomeruli and glomerular capillaries (31, 32). In addition, recent studies have shown
256 that the association between the expression of inflammatory genes such as CCL2 and
257 CCL19 and the development of DN can also be replicated in mice, and genetic or
258 pharmacological intervention studies have shown that increased levels of cytokines
259 contribute to the development of DN (33, 34). However, some of these selected genes,
260 such as GPR18, SST, and ADRA2A were still lacking exploration for their functions in
261 DN.

262 WGCNA is a systems biology method for describing pairwise relationships between
263 gene transcripts and a comprehensive collection of R functions for performing aspects
264 of weighted correlation network analysis (35). Through intensive and systematic

265 reanalysis of the GSE30528 dataset, we determined that the green module is
266 significantly associated with clinical traits in DN patients. To find more significant
267 genes in DN, we screened 68 genes out from the green module with a cut-off of module
268 membership (MM) >0.8 and gene significance (GS) >0.7. After filtering for GS and
269 MM values, we eventually obtained 10 hub genes (RNASE6, CD1C, SASH3, COL1A2,
270 CD163, CLEC10A, MOXD1, IQGAP2, GHR). Among these ten genes, RNASE6,
271 CD1C, and COL1A2 have been demonstrated to exert essential roles in the
272 pathogenesis of DN (36-38). And CD163 was considered as an early biomarker of
273 nephropathy in Swedish patients with diabetes of 15–34 years of age (39). Finally, the
274 expression level of these hub genes was validated in the GSE96804 dataset. The results
275 of expression level were similar by clinical features.

276 **Conclusion**

277 In summary, a series of bioinformatics analyses of DN samples were performed in the
278 present study. We selected DEGs obtained from the GSE63514 dataset and explored
279 their functions and pathways that may be involved in the initiation and progression of
280 DN. Furthermore, hub genes were identified according to the analysis of WGCNA,
281 revealing an important role of the glomeruli in the pathological mechanisms of diabetic
282 nephropathy. The potential of these key genes for diagnostic, prognostic, and
283 therapeutic targeting deserves further exploration and demonstration.

284 **Availability of data and materials**

285 All data can be accessed in the GEO database
286 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30528>,<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96804>)

287 [m.nih.gov/geo/query/acc.cgi?acc=GSE96804](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96804)).

288 **References**

- 289 1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its
290 complications. *Nat Rev Endocrinol.* 2018;14(2):88-98.
- 291 2. Campbell JE, Drucker DJ. Islet alpha cells and glucagon--critical regulators of energy homeostasis.
292 *Nat Rev Endocrinol.* 2015;11(6):329-38.
- 293 3. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology,
294 clinical consequences, and medical therapy: part I. *Eur Heart J.* 2013;34(31):2436-43.
- 295 4. Li JP, Wei W, Li XX, Xu M. Regulation of NLRP3 inflammasome by CD38 through cADPR-
296 mediated Ca(2+) release in vascular smooth muscle cells in diabetic mice. *Life Sci.* 2020;255:117758.
- 297 5. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev.* 2013;93(1):137-88.
- 298 6. Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond
299 glucose control. *BMJ.* 2017;356:i6505.
- 300 7. Falkevall A, Mehlem A, Palombo I, Heller Sahlgren B, Ebarasi L, He L, et al. Reducing VEGF-B
301 Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease. *Cell Metab.*
302 2017;25(3):713-26.
- 303 8. Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic
304 memory. *Nat Rev Nephrol.* 2019;15(6):327-45.
- 305 9. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming
306 growth factor-beta as a key mediator. *Diabetes.* 1995;44(10):1139-46.
- 307 10. Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, et al. Role of the Akt/FoxO3a pathway in
308 TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease.

- 309 J Am Soc Nephrol. 2006;17(12):3325-35.
- 310 11. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic
311 nephropathy. *Nat Rev Nephrol*. 2010;6(6):319-30.
- 312 12. Lambers Heerspink HJ, Oberbauer R, Perco P, Heinzl A, Heinze G, Mayer G, et al. Drugs meeting
313 the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized
314 medicine. *Nephrol Dial Transplant*. 2015;30 Suppl 4:iv105-12.
- 315 13. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive
316 for functional genomics data sets--update. *Nucleic Acids Res*. 2013;41(Database issue):D991-5.
- 317 14. Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis.
318 *Bioinformatics*. 2012;28(4):573-80.
- 319 15. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression
320 analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015;43(7):e47.
- 321 16. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes
322 among gene clusters. *OMICS*. 2012;16(5):284-7.
- 323 17. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-
324 networks from complex interactome. *BMC Syst Biol*. 2014;8 Suppl 4:S11.
- 325 18. Bus P, Chua JS, Klessens CQF, Zandbergen M, Wolterbeek R, van Kooten C, et al. Complement
326 Activation in Patients With Diabetic Nephropathy. *Kidney Int Rep*. 2018;3(2):302-13.
- 327 19. Palviainen MJ, Junnikkala S, Raekallio M, Meri S, Vainio O. Activation of complement system in
328 kidney after ketoprofen-induced kidney injury in sheep. *Acta Vet Scand*. 2015;57:15.
- 329 20. Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. *Int J Biol*
330 *Sci*. 2018;14(11):1483-96.

- 331 21. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J
332 Clin Invest. 2014;124(6):2333-40.
- 333 22. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis
334 of human diabetic kidney disease. Diabetes. 2011;60(9):2354-69.
- 335 23. Fu J, Akat KM, Sun ZG, Zhang WJ, Schlondorff D, Liu ZH, et al. Single-Cell RNA Profiling of
336 Glomerular Cells Shows Dynamic Changes in Experimental Diabetic Kidney Disease. Journal of the
337 American Society of Nephrology. 2019;30(4):533-45.
- 338 24. Aricescu AR, Jones EY. Immunoglobulin superfamily cell adhesion molecules: zippers and signals.
339 Curr Opin Cell Biol. 2007;19(5):543-50.
- 340 25. Schnoor M, Alcaide P, Voisin MB, van Buul JD. Crossing the Vascular Wall: Common and Unique
341 Mechanisms Exploited by Different Leukocyte Subsets during Extravasation. Mediators Inflamm.
342 2015;2015:946509.
- 343 26. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag.
344 2007;3(6):853-76.
- 345 27. Deng X, Rui W, Zhang F, Ding W. PM2.5 induces Nrf2-mediated defense mechanisms against
346 oxidative stress by activating PIK3/AKT signaling pathway in human lung alveolar epithelial A549 cells.
347 Cell Biol Toxicol. 2013;29(3):143-57.
- 348 28. Yay A, Akkus D, Yapislar H, Balcioglu E, Sonmez MF, Ozdamar S. Antioxidant effect of carnosine
349 treatment on renal oxidative stress in streptozotocin-induced diabetic rats. Biotech Histochem.
350 2014;89(8):552-7.
- 351 29. Piao Y, Yin D. Mechanism underlying treatment of diabetic kidney disease using Traditional
352 Chinese Medicine based on theory of Yin and Yang balance. J Tradit Chin Med. 2018;38(5):797-802.

353 30. Lee WC, Li LC, Ng HY, Lin PT, Chiou TT, Kuo WH, et al. Urinary Exosomal MicroRNA
354 Signatures in Nephrotic, Biopsy-Proven Diabetic Nephropathy. *J Clin Med.* 2020;9(4).

355 31. Wehner H, Hohn D, Faix-Schade U, Huber H, Walzer P. Glomerular changes in mice with
356 spontaneous hereditary diabetes. *Lab Invest.* 1972;27(3):331-40.

357 32. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2
358 diabetic nephropathy: correlation with diabetic state and progressive renal injury. *Kidney Int.*
359 2004;65(1):116-28.

360 33. Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. *Nat Rev*
361 *Drug Discov.* 2016;15(8):568-88.

362 34. Anderberg RJ, Meek RL, Hudkins KL, Cooney SK, Alpers CE, Leboeuf RC, et al. Serum amyloid
363 A and inflammation in diabetic kidney disease and podocytes. *Lab Invest.* 2015;95(6):697.

364 35. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC*
365 *Bioinformatics.* 2008;9:559.

366 36. Cui C, Cui Y, Fu Y, Ma S, Zhang S. Microarray analysis reveals gene and microRNA signatures in
367 diabetic kidney disease. *Mol Med Rep.* 2018;17(2):2161-8.

368 37. Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. *Nat Rev Nephrol.* 2020;16(4):206-

369 38. Kelly KJ, Liu Y, Zhang J, Dominguez JH. Renal C3 complement component: feed forward to
370 diabetic kidney disease. *Am J Nephrol.* 2015;41(1):48-56.

371 39. Samuelsson M, Dereke J, Svensson MK, Landin-Olsson M, Hillman M, on the behalf of the DSg.
372 Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with
373 diabetes, 15-34 years of age: a prospective cohort study. *Diabetol Metab Syndr.* 2017;9:41.

374

375 **Acknowledgements**

376 Not applicable.

377 **Funding**

378 This work was supported by the National Key Research and Development Program
379 (2017YFC0907103) and Key research and Nanning Key Research and Development
380 Program (20183039-2).

381 **Author information**

382 **Affiliations**

383 Department of Epidemiology and Health Statistics, School of Public Health, Guangxi
384 Medical University, Nanning 530021, Guangxi, China.

385 **Contributions**

386 Contribution to the concept or design of the work: XQQ acquisition, analysis or
387 interpretation of data: CCC. All authors read and approved the final manuscript.

388 **Corresponding author**

389 Correspondence to Xiaoqiang Qiu.

390 **Ethics declarations**

391 **Ethics approval and consent to participate**

392 Not applicable.

393 **Consent for publication**

394 Not applicable.

395 **Competing interests**

396 All the authors declare they have no competing interests.

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436 **Tables:**

Gene	Gene significance	Module membership
RNASE6	0.82	0.93
CD1C	0.80	0.92
SASH3	0.77	0.91
COL1A2	0.75	0.90
MS4A6A	0.77	0.88
CD163	0.81	0.84
CLEC10A	0.78	0.83
MOXD1	0.76	0.83
IQGAP2	-0.80	-0.80
GHR	-0.79	-0.89

437 **Table 1** Hub genes of the module green. Hub genes were defined as having a gene
438 significance over 0.7 and a module membership over 0.8.

439

440

441


442

443

444

445

446



448

449 **Figure 1** The flow diagram of data preparing, processing, and analysis in our study (A).

450 The volcano map of DEGs, identified in GSE30528, between DN and normal glomeruli

451 samples (B). The red points in the volcano plots represent upregulation and the green


452 plots represent downregulation. Heatmap of the top 200 DEGs (top 100 up-regulated

453 DEGs and top 100 down-regulated DEGs) according to the value of $|\logFC|$ (C). The

454 color from green to red in the heatmap shows the process from low expression to high

455 expression.

456




457

458 **Figure 2** Gene Ontology analysis of the DEGs regarding the biological process(A),

459 cellular component(B), and molecular function (C). The top 15 significant terms of


460 enrichment analysis are shown in the bar chart.

461



462


463 **Figure 3** The top 20 terms of KEGG pathway enrichment analysis in the dot plot (A).



464

465 **Figure 4** Protein-protein interaction network of the DEGs (A). Top 30 essential genes

466 in the PPI network (B).



467


468 **Figure 5** Analysis of network topology for various soft-thresholding powers. The x-

469 axis reflects the soft-thresholding power. The y-axis reflects the scale-free topology

470 model fit index (A). The x-axis reflects the soft-thresholding power. The y-axis reflects

471 the mean connectivity (degree) (B).


472



473


474 **Figure 6** Clustering dendrogram of genes, with dissimilarity based on the topological

475 overlap, together with assigned module colors (A).



476

477 **Figure 7** Visualization of the WGCNA network using a heatmap plot. The heatmap
 478 depicts the topological overlap matrix (TOM) among all modules included in the
 479 analysis. The light color represents a low overlap, and the progressively darker red color
 480 represents an increasing overlap (A).




481

482 **Figure 8** Module–trait associations. Each row corresponds to a module, and each

483 column corresponds to a trait. Each cell contains the corresponding correlation and P-

484 value. The table is color-coded by correlation according to the color legend (A).



485

486 **Figure 9** Scatter plot of the expression level of key genes (A-J). The blue scatter reflects

487 the control group, and the red scatter reflects the T2DM group. * P < 0.05,

488 **P<0.01,***P<0.001,****P<0.0001.